Eric Loumeau Sells 12,500 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 12,500 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $44.86, for a total transaction of $560,750.00. Following the completion of the sale, the insider directly owned 9,088 shares in the company, valued at approximately $407,687.68. The trade was a 57.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $49.08 on Friday. The firm has a market capitalization of $1.36 billion, a P/E ratio of -17.40 and a beta of 0.29. The stock has a 50-day simple moving average of $38.80 and a two-hundred day simple moving average of $28.92. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $49.90.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. As a group, analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has initiated a share buyback program on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Wells Fargo & Company lifted their price target on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Truist Financial boosted their price objective on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Barclays reduced their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a research note on Wednesday. HC Wainwright dropped their price target on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. Finally, Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.40.

Key Stores Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Guggenheim sharply raised its price target to $140 from $100, signaling strong analyst confidence in AnaptysBio’s pipeline and upside potential—this is a major bullish catalyst that can attract buyers and momentum investors. Guggenheim target raise
• Positive Sentiment: Recent company fundamentals support a stronger valuation: AnaptysBio reported a large revenue beat and positive quarterly EPS last quarter and the board has authorized a $100M buyback (up to ~9.6% of shares), both of which are supportive of higher share prices and institutional interest. MarketBeat company summary
• Neutral Sentiment: Institutional activity is mixed but constructive: some funds increased positions in Q3 while others adjusted exposure—this shows active interest but not a clear one-way flow. Monitor 13F updates for directional confirmation. Institutional holdings
• Negative Sentiment: CFO Dennis Mulroy sold 15,725 shares (~$705k) in mid‑December, reducing his stake by ~62.6%—a large, recent insider sale that can raise investor concern about near‑term insider sentiment. CFO Form 4
• Negative Sentiment: Executive Eric J. Loumeau completed multiple sales (10,000 and other tranches totaling sizable reductions), cutting his position by ~50–60% in filings—additional insider selling increases short‑term downside risk and can sap sentiment. Insider trades alert Loumeau Form 4
• Negative Sentiment: Barclays lowered its price target to $55 from $70 on Dec. 17, which is a modest negative signal that may temper enthusiasm from other bullish research. Barclays target cut

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ANAB. Tudor Investment Corp ET AL boosted its stake in AnaptysBio by 47.2% during the 3rd quarter. Tudor Investment Corp ET AL now owns 13,869 shares of the biotechnology company’s stock worth $425,000 after purchasing an additional 4,450 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of AnaptysBio by 2.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock worth $11,588,000 after buying an additional 10,005 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in AnaptysBio during the third quarter worth about $315,000. Larson Financial Group LLC grew its stake in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares in the last quarter. Finally, Granahan Investment Management LLC raised its holdings in AnaptysBio by 12.2% in the 3rd quarter. Granahan Investment Management LLC now owns 147,773 shares of the biotechnology company’s stock valued at $4,525,000 after acquiring an additional 16,118 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.